Evaluation of the mutagenic effects of Molnupiravir and N4‐hydroxycytidine in bacterial and mammalian cells by HiFi sequencing
Sign Up to like & getrecommendations! Published in 2022 at "Environmental and Molecular Mutagenesis"
DOI: 10.1002/em.22510
Abstract: Molnupiravir (MOV) is used to treat COVID‐19. In cells, MOV is converted to the ribonucleoside analog N4‐hydroxycytidine (NHC) and incorporated into the SARS‐CoV‐2 RNA genome during its replication, resulting in RNA mutations. The widespread accumulation… read more here.
Keywords: molnupiravir hydroxycytidine; mutagenic effects; effects molnupiravir; evaluation mutagenic ... See more keywords